OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Andreadis Discusses the Role of Ibrutinib in DLBCL

November 14th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with diffuse large B-cell lymphoma.

Dr. Parker on the Rationale for Radiotherapy in Metastatic Prostate Cancer

November 14th 2018

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the rationale for radiotherapy in the treatment of newly-diagnosed metastatic prostate cancer.

Dr. Nguyen on Treatment Approaches for Patients With Advanced Ovarian Cancer

November 14th 2018

Trung Nguyen, DO, MBA, clinical assistant professor, Obstetrics and Gynecology, Gynecologic Oncology, Stanford Medicine, discusses treatment approaches for patients with advanced ovarian cancer.

Dr. Feldman on the Future of Durvalumab and Tremilimumab in NSCLC

November 14th 2018

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses the future of durvalumab (Imfinzi) and tremelimumab in non–small cell lung cancer (NSCLC).

Dr. Rugo on Resistance to CDK4/6 Inhibitors in HR+ Breast Cancer

November 14th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses resistance to CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Dr. Lassen Discusses TRK Fusions in Pediatric Patients

November 14th 2018

Ulrik Lassen, MD, PhD, head of the Phase I Unit at Rigshospitalet, discusses TRK fusions in pediatric patients with cancer.

Dr. Powles on Biomarkers for Immunotherapy in Bladder Cancer

November 14th 2018

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses biomarkers for immunotherapy in bladder cancer.

Dr. Gorantla on the Impact of the APHINITY Trial in HER2+ Breast Cancer

November 14th 2018

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, discusses the impact of the APHINITY trial on the treatment of patients with HER2-positive breast cancer.

Dr. Choueiri on Biomarkers in RCC

November 14th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses biomarkers in renal cell carcinoma.

Dr. Pegram on Future Impact of Biosimilars in Oncology

November 13th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the future impact of biosimilars in oncology.

Dr. O'Connor on Real-World Results With Regorafenib in mCRC

November 13th 2018

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses real-world results with regorafenib (Stivarga) in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Green on Treatment Regimens for Patients With Multiple Myeloma in Early Relapse

November 13th 2018

Michael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.

Dr. Dorigo on Immunotherapy in Ovarian Cancer

November 13th 2018

Oliver Dorigo, MD, PhD, associate professor of Obstetrics and Gynecology, Stanford University Medical Center, Stanford Medicine, discusses the use of immunotherapy in the treatment of patients with ovarian cancer.

Dr. Shimomura Discusses the HERB TEA Study in HER2+ Breast Cancer

November 13th 2018

Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, discusses the HERB TEA trial (JCOG1607) in patients with HER2-positive breast cancer.

Dr. Mody Discusses Treatment Options for HCC

November 13th 2018

Kabir Mody, MD, medical oncologist, Mayo Clinic, discusses treatment options for patients with hepatocellular carcinoma.

Dr. Rischin Discusses the Future of Cemiplimab in Cervical Cancer

November 13th 2018

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the next steps with cemiplimab (Libtayo) in the treatment landscape of cervical cancer.

Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian Cancer

November 10th 2018

Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.

Dr. Scherber Discusses Ruxolitinib Failure in Myelofibrosis

November 10th 2018

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses ruxolitinib (Jakafi) failure in patients with myelofibrosis (MF).

Dr. Emberton Addresses Issues in Diagnosing Localized Prostate Cancer

November 10th 2018

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, addresses issues in the diagnosis of localized prostate cancer.

Dr. Rahman on Understanding the Role of Biosimilars in Oncology

November 9th 2018

Mohammed J. Rahman, MD, oncologist, University of Pittsburgh Medical Center, discusses his understanding of the role of biosimilars in oncology.